@article{326fdc18476c48f3b8b2253c583a7878,
title = "National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - Executive summary",
abstract = "Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol - non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol - as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia.",
keywords = "Atherogenic cholesterol, Atherosclerotic cardiovascular disease, Clinical recommendations, Coronary heart disease, Dyslipidemia, Lipoproteins, Low-density lipoprotein cholesterol",
author = "Jacobson, {Terry A.} and Ito, {Matthew K.} and Maki, {Kevin C.} and Orringer, {Carl E.} and Bays, {Harold E.} and Jones, {Peter H.} and McKenney, {James M.} and Grundy, {Scott M} and Gill, {Edward A.} and Wild, {Robert A.} and Wilson, {Don P.} and Brown, {W. Virgil}",
note = "Funding Information: Dr. Jacobson discloses that in the past 12 months he has received consulting fees from Merck and Co., Amarin, AstraZeneca, and Regeneron/Sanofi-Aventis. Dr. Ito discloses that he received a research grant from Kowa Pharmaceuticals and consulting honorarium from Regeneron/Sanofi. Dr. Maki discloses that he has received consulting fees and research grants from Abbott Laboratories, Amarin, Matinas BioPharma, Omthera (now a subsidiary of Astra Zeneca), Pharmavite and Trygg Pharmaceuticals and that he was an employee of Biofortis, Inc. Dr. Orringer discloses that he has received consulting fees from Merck. Dr. Bays discloses that he has received research grants from Arena Pharmaceuticals, Boehringer Ingelheim, Cargill Inc., GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics, Shionogi, Takeda, Stratum Nutrition, California Raisin Board, Esperion, Essentialis, Forest, Gilead, Given, Hoffman LaRoche, Home Access, Novartis, Omthera, Pfizer, Trygg Pharmaceuticals, TWI Bio, Xoma, Ardea Inc., High Point Pharmaceuticals, LLC, Micropharma Limited, Transtech Pharma, Inc., TIMI, Pozen, Regeneron, and Elcelyx; and honoraria/research grants from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Catabasis, Daiichi Sankyo, Inc., Eisai, Merck, VIVUS, Zeomedex, and WPU. Dr. Jones discloses that he has received consulting honoraria from AstraZeneca, Atherotech Diagnostic Lab, Daiichi Sankyo, Inc., Merck and Co., and Sanofi/Regeneron. Dr. McKenney discloses that the company with which he is employed has received research grants from Sanofi, Regeneron, Amgen, Pfizer, Lily, and Esperion. Dr. Grundy discloses that he received an honorarium as a consultant to Sanofi. Dr. Gill discloses that he has received consulting fees from Philips Medical Systems. Dr. Wild discloses that he has received consulting honoraria from the National Institutes of Health, the Food and Drug Administration, and Atherotech, Inc. Dr. Wilson discloses that he has been a speaker for Osler Institute-Pediatric Review Course and participated on the advisory board of Aegerion Pharmaceuticals, and further discloses that he has received research funding from Merck Sharpe & Dohme and Novo Nordisk Inc. Dr. Brown is editor of the Journal of Clinical Lipidology and further discloses that he has received consulting fees/honoraria from Amgen, Bristol-Myers Squibb, Genzyme, Pfizer, Inc., LipoScience, Inc., Merck and Co., Catabasis, GlaxoSmithKline, Medtelligence, and Vindico. Publisher Copyright: {\textcopyright} 2014 National Lipid Association. All rights reserved.",
year = "2014",
month = sep,
day = "1",
doi = "10.1016/j.jacl.2014.07.007",
language = "English (US)",
volume = "8",
pages = "473--488",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "5",
}